Acthar® Gel (repository corticotropin injection) Reference Bibliography
This bibliography contains verifiable peer-reviewed manuscripts and abstracts on the use of Acthar Gel, as well as publications supported by Mallinckrodt that relate to Acthar directly or indirectly. Human and preclinical studies, health economic and outcomes analyses (HEOR), reports and reviews are included and, where available, links to PubMed are provided.
Updated May 2019

Nephrology


52. Tumlin JA, Rovin BH, Paxton WG, Ayoub I, Almaani S, Caster DJ, Appel AS, Appel GB. A Prospective, Open Label Study of the safety and treatment efficacy of ACTHar Gel for


**Nephrology HEOR**


**Neurology**


95. Due BR, Becker PM, Coyle PK. A prospective observational registry of repository corticotropin injection for the treatment of multiple sclerosis relapse: baseline characteristics and interim results [CMSC abstract RT02] *Int J MS Care.* 2018;20(suppl 1):89.


165. Hansen R, Gold L, Schepman P, Niewoehner J, Philbin M. Economic consequences of early versus late use of adrenocorticotropic hormone therapy in infantile spasms [WCI abstract LB10]. Late-breaker abstract presented at World Congress of Inflammation Meeting; August 8-12, 2015; Boston, MA. 2015


Ophthalmology


Ophthalmology HEOR


Pulmonology


Pulmonology – HEOR


Fernandez A. Interim results of an open-label study assessing efficacy and safety of adrenocorticotropic hormone gel for treatment of refractory cutaneous manifestations of dermatomyositis [ACR abstract 2287]. Arthritis Rheumatol. 2018;70(S9):2520-2521.


Fiechtner JJ, Montroy T. Treatment of moderately to severely active systemic lupus erythematosus with adrenocorticotropic hormone: a single-site, open-label trial. Lupus. 2014;23(9):905-912. Link


239. Gillis TM, Crane M, Hinkle C, Wei N. H.P. Acthar® Gel (repository corticotropin injection) as adjunctive therapy in patients with rheumatoid arthritis who have failed at least three biologic therapies with different modes of action [EULAR abstract AB0502]. *Ann Rheum Dis*. 2015;74(suppl 2):1066-1066


261. Zutshi DW, Friedman M, Ansell BM. Corticotrophin therapy in juvenile chronic polyarthritis (still's disease) and effect on growth. *Arch Dis Child.* 1971;46(249):584-593. Link

**Rheumatology – HEOR**


17

Other


281. Baram TZ. What are the reasons for the strikingly different approaches to the use of ACTH in infants with West Syndrome? Brain and Development. 2001;7:647-648. [Link]


308. Clemson CM, Yost J, Taylor AW. The role of alpha-MSH as a modulator of ocular immunobiology exemplifies mechanistic differences between melanocortins and steroids. *Ocul Immunol Inflamm.* 2016;1-11. [Link]


312. Decker D, Higgins P, Bendale A, Becker P. Repository corticotropin injection (H.P. Acthar® Gel) attenuates established collagen-induced arthritis when used alone or as adjuvant therapy with Etanercept (Enbrel®) [AAI abstract THER5P.902]. *J Immunol.* 2015;194(suppl 1):139.4-139.4

Inclusion body myositis (IBM) symptom flares and associated impact from the patient

Kontekakis A, Nelson W, Christopher
1990;No. 4:238

Kongelbeck SR. Discharge planning for the child with infantile spasms.
2016;55(3):71

Kirkil G, Baughman RP. The current management of sarcoidosis.

Meta
adrenocorticotropic hormone treatment in glomerular diseases: A systematic review and
analysis.

Kittanamongkolchai W, Cheungpasitporn W, Zand L. Efficacy and safety of
deoxycortisol relative to other reduced zona fasciculata steroids.

Hypopituitarism produces asynchronous increases of deoxycorticosterone and 11-
hydroxycorticosteroid production [Trends Endocrinol Metab.

Kater CE, Biglieri EG, Faical S. Continuous adrenocorticotropic hormone administration in
hypopituitarism produces asynchronous increases of deoxycorticosterone and 11-
dehydocortisol relative to other reduced zona fasciculata steroids.

J Clin Invest. 1967;46(2):196-204. Link


Gentry PA, Liptrap RM, Tremblay RR, Lichen L, Ross ML. Adrenocorticotropic hormone fails
to alter plasma fibrinogen and fibronectin values in calves but does so in rabbits. Vet Res
Commun. 1992;16(4):253-264. Link

Gitelson S. The effect of ACTH and cortisone on the blood pyruvic acid level. Acta Endocrinol

Go T. Sequential MRI in chronic meningitis during adrenocorticotropic hormone treatment for

Gong R. The renaissance of corticotropin therapy in proteinuric nephropathies. Nat Rev
Nephrol. 2012;8:122-128. Link

Hayes K, Warner EA, Bollinger C, Wright D, Fitch RM. Differential effects of Acthar® Gel and
methylprednisolone in a preclinical rodent model of FSGS [ASN abstract PUB447]. J Am Soc

Hayes K, Warner E, Bollinger C, Wright D, Fitch R. H.P. Acthar Gel inhibits fibrosis, renal

Healy LM, Jang JH, Lin YH, Rao V, Antel JP, Wright D. Melanocortin receptor mediated anti-
inflammatory effect of repository corticotropin injection on human monocyte derived


Higgins P, Decker D, Becker P. Immunomodulatory effects of repository corticotropin

Higgins P, Decker D, Becker P. Inhibition of a streptococcal cell wall model of arthritis flare by

Higgins P, Young D. Inhibitory effects of Acthar Gel in the passive Heymann nephritis model

Hogan JJ, Jai R, Gerald BA, Andrew SB, Pietro AC, Maya KR. Treatment of resistant primary
cranial segmental glomerulosclerosis (FSGS) with adrenocorticotropic hormone (ACTH) gel
[ASN abstract SA-PO381]. J Am Soc Nephrol. 2012;23(suppl):725A


Jensen MA, Abraham P, Reder AT, Arnason BGW. Co-production of GM-CSF, IL-22, or IL-
17F identifies a pathogenic high IL-17A-producing T cell subset from MS patients that is

Kater CE, Irony I, Biglieri EG, Faical S. Continuous adrenocorticotropic hormone administration in
hypopituitarism produces asynchronous increases of deoxycorticosterone and 11-
dehydocorticosteroid production [Trends Endocrinol Metab.

Kittanamongkolchai W, Cheungpasitporn W, Zand L. Efficacy and safety of
adrenocorticotropic hormone treatment in glomerular diseases: A systematic review and

2016;55(3):71-84.

Kongelbeck SR. Discharge planning for the child with infantile spasms. J Neurosci Nurs.
1990;No. 4:238-244. Link

Kontekakis A, Nelson W, Christopher-Stine L, Kelly W, Kobert L, Opong-Owusu B, Reed M. Inclusion body myositis (IBM) symptom flares and associated impact from the patient


345. Lisak RP, Nedelkoska L, Benjamins JA. Melanocortin 4 receptors on oligodendrocytes and oligodendrocyte precursors signal ACTH protection from in vitro death induced by mechanisms involved in cell damage in multiple sclerosis.[ECTRIMS abstract P579]. Mult Scler. 2015;23(11 suppl 1):273,

346. Lisak R, Nedelkoska L, Benjamins J. ACTH1-39 protection of oligodendrocytes from damage relevant to multiple sclerosis involves both direct and indirect mechanisms. [AAN abstract P2.189]. Neurology. 2015;84(suppl 14):P2.189


358. Montroy T, Fiechtner JJ. A single-site, investigator initiated, open-label trial of the adrenocorticotropic hormone (ACTH) analogue HP Acthar Gel (repository corticotropin injection) among subjects with moderately to severely active systemic lupus erythematosus (SLE) [EULAR abstract AB0382]. *Ann Rheum Dis.* 2013;72(suppl 3):904


361. Obi O, Judson M, Maier L, Wells A, Baughman R. Role of baseline dyspnea index (BDI) and transition dyspnea index (TDI) as a measure of self-reported health related quality of life in sarcoidosis patients [ATS abstract A5609]. *Am J Respir Crit Care Med.* 2019;199:A5609.


